Research Institute Diabetes Academy Mergentheim, Bad Mergentheim, Germany; Department of Clinical Psychology and Psychotherapy, University of Bamberg, Bamberg, Germany.
Research Institute Diabetes Academy Mergentheim, Bad Mergentheim, Germany; Department of Clinical Psychology and Psychotherapy, University of Bamberg, Bamberg, Germany; Diabetes Clinic Mergentheim, Bad Mergentheim, Germany.
Lancet Diabetes Endocrinol. 2020 May;8(5):436-446. doi: 10.1016/S2213-8587(20)30042-5.
Diabetic ketoacidosis (DKA) is a serious acute complication of type 1 diabetes, which is receiving more attention given the increased DKA risk associated with SGLT inhibitors. Sociodemographic and modifiable risk factors were identified with strong evidence for an increased risk of DKA, including socioeconomic disadvantage, adolescent age (13-25 years), female sex, high HbA, previous DKA, and psychiatric comorbidities (eg, eating disorders and depression). Possible prevention strategies, which include the identification of people at risk based on non-modifiable sociodemographic risk factors, are proposed. As a second risk mitigation strategy, structured diabetes self-management education that addresses modifiable risk factors can be used. Evidence has found that structured education leads to reduced DKA rates. Knowledge of these risk factors and potent risk mitigation strategies are important to identify subgroups of people with an elevated DKA risk. This knowledge should also be used when adjunct therapy options with an increased DKA risk are considered. Prevention of DKA in people with type 1 diabetes is an important clinical task, which should also be addressed when SGLT inhibitors are part of therapy.
糖尿病酮症酸中毒 (DKA) 是 1 型糖尿病的一种严重急性并发症,鉴于 SGLT 抑制剂相关的 DKA 风险增加,该疾病受到了更多关注。已经确定了与 DKA 风险增加具有强证据的社会人口学和可改变的危险因素,包括社会经济劣势、青少年年龄(13-25 岁)、女性、高 HbA、既往 DKA 和精神共病(如,饮食失调和抑郁)。提出了可能的预防策略,包括基于不可改变的社会人口学危险因素识别处于风险中的人群。作为第二项风险缓解策略,可以使用针对可改变危险因素的结构化糖尿病自我管理教育。有证据表明,结构化教育可降低 DKA 发生率。了解这些危险因素和有效的风险缓解策略对于确定 DKA 风险升高的人群亚组很重要。当考虑具有增加 DKA 风险的附加治疗选择时,也应了解这些知识。预防 1 型糖尿病患者的 DKA 是一项重要的临床任务,当 SGLT 抑制剂成为治疗的一部分时,也应解决这一问题。